Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

BACKGROUND: Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with unresectable pancreatic cancer was deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Gueorguieva, Ivelina, Lahn, Michael M. F., Blunt, Al, Benhadji, Karim A., Tabernero, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251034/
https://www.ncbi.nlm.nih.gov/pubmed/30318515
http://dx.doi.org/10.1038/s41416-018-0246-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251034/
https://www.ncbi.nlm.nih.gov/pubmed/30318515
http://dx.doi.org/10.1038/s41416-018-0246-z

Ejemplares similares